EP0512525A1 — Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist
Assigned to Otsuka Pharmaceutical Co Ltd · Expires 1992-11-11 · 34y expired
What this patent protects
Desclosed is carbostyril derivatives of the general formula wherein R¹ is a halogen, a hydroxyl, lower alkoxy, lower alkyl, lower alkenyloxy, amino, lower-alkanoyl amino or lower alkylthio group, R² is a phenyl group which may optioanlly have one or two substituents, A i…
USPTO Abstract
Desclosed is carbostyril derivatives of the general formula wherein R¹ is a halogen, a hydroxyl, lower alkoxy, lower alkyl, lower alkenyloxy, amino, lower-alkanoyl amino or lower alkylthio group, R² is a phenyl group which may optioanlly have one or two substituents, A is a lower alkylene group, and n is an integer of 1 or 2 and wherein the carbon-carbon bond between the positions 3 and 4 of the carbostyril skeleton may be a single bond or a double bond, and salts thereof, and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist.
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.